Liver targeting of hepatitis-B antiviral lamivudine using the HepDirect™ prodrug technology

Nucleosides, Nucleotides and Nucleic Acids

Volumn 24, Issue 5-7, 2005, Pages 375-381

  Reddy, K Raja ^a   Colby, Timothy J ^a   Fujitaki, James M ^a   Van Poelje, Paul D ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NUCLEOSIDE; PHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PRODRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; HEPATITIS B; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; RAT; TARGET CELL; TECHNOLOGY;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CELLS, CULTURED; HEPATITIS B; HEPATOCYTES; HUMANS; KINETICS; LAMIVUDINE; LIVER; MICROSOMES, LIVER; MODELS, CHEMICAL; PHOSPHATES; PHOSPHORYLATION; PRODRUGS; RATS; TIME FACTORS;

ANIMALIA; LETTUCE MOSAIC VIRUS;

EID: 26644440444     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1081/NCN-200059781     Document Type: Conference Paper

References (19)

1. Lavanchy, D.J. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Viral Hepat. 2004, 11(2), 97-107.
2. Wong, D.K.H.; Cheung, A.M.; O'Rourke, K.; Naylor, C.D.; Detsky, A.S.; Heathcote, J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993, 119, 312-323.
3. Lai, C.L.; Chien, R.N.; Leung, N.W.Y.; Chiang, T.T.; Guan, R.; Tai, D.I.; Ng, K.Y.; Wu, P.C.; Dent, J.C.; Barber, J.; Stephenson, S.L.; Gray, D.F. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N. Eng. J. Med. 1998, 339, 61-68.
4. Lok, A.S.; Hussain, M.; Cursano, C.; Margotti, M.; Gramenzi, A.; Grazi, G.L.; Jovine, E.; Benardi, M.; Andreone, P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000, 32(5), 1145-1153.
5. Marcellin, P.; Chang, T.T.; Lim, S.G.; Tong, M.J.; Sievert, W.; Shiffman, M.L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M.S.; Xiong, S.; Fry, J.; Brosgart, C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003, 348(9), 808-816.
6. Tanji, N.; Tanji, K.; Kambham, N.; Markowitz, G.S.; Bell, A.; D'agati, V.D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Human Pathol. 2001, 32(7), 734-740.
7. Kewn, S.; Hoggard, P.G.; Sales, S.D.; Johnson, M.A.; Back, D.J. The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. Br. J. Clin. Pharmacol. 2000, 50, 597-604.
8. Erion, M.D.; Reddy, K.R.; Boyer, S.H.; Matelich, M.C.; Gomez-Galeno, J.; Lemus, R.H.; Ugarkar, B.G.; Colby, T.J.; Schanzer, J.; van Poelje, P.D. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 2004, 126, 5154-5163.
9. Erion, M.D.; van Poelje, P.D.; MacKenna, D.A.; Colby, T.J.; Montag, A.; Fujitaki, J.M.; Linemeyer, D.L.; Bullogh, D.A. Liver-targeted drug delivery using HepDirect™ prodrugs. J. Pharm. Exp. Ther. 2005, 308, in press.
10. Schultz, C. Prodrugs of biologically active phosphate esters. Bioorg. Med. Chem. 2003, 11(6), 885-898.
11. Meunier, B.; de Visser, S.P.; Ahaik, S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 2004, 104, 3947-3980.
12. Turner, J.A. A general approach to the synthesis of 1,6-, 1,7-, and 1,8-naphthyridines. J. Org. Chem. 1990, 55, 4744-4750.
13. Milton, J.; Brand, S.; Jones, M.F.; Rayner, C.M. Enantioselective enzymatic synthesis of the anti-viral agent lamivudine (3TC™). Tetrahedron Lett. 1995, 36(38), 6961-6964.
14. Beaucage, S.L.; Iyer, R.P. The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications. Tetrahedron 1993, 49, 6123-6194.
15. 2/AIBN to P-chiral phosphates. J. Am. Chem. Soc. 1989, 111, 3981-3987.
16. Mosbo, J.; Verkade, J.G.A. Dipole moment, nuclear magnetic resonance, and infrared studies of phosphorus configurations and equilibriums in 2-R-2-oxo-1,3,2-dioxaphosphorinanes. J. Org. Chem. 1977, 42, 1549-1555.
17. Cooper, D.B.; Harrison, J.M.; Inch, T.D.; Lewis, G.J. Use of carbohydrate derivatives for studies of phosphorus stereochemistry. Part II. Synthesis and configurational assignments of 1,-3,2-oxathiaphosphorinan-2-ones and 1,3,2-dioxaphosphorinan-2-thiones. J. Chem. Soc., Perkin Trans, 1 1974, 1049-1052.
18. de Waziers, I.; Cugnenc, P.H.; Yang, C.S.; Leroux, J.P.; Beaune, P.H. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 1990, 253(1), 387-394.
19. Liu, C. C.; Chao, Y.-C.; Lai, M.-Y.; Chang, T.-T.; Chuang, W.-L.; Yang, S.-S.; Braeckman, R.; Chen, D-S. Safety, tolerance, pharmacokinetics and pharmacodynamics of Remofovir, a liver-targeting prodrug of PMEA in HBV patients following daily dosing for 28 days. Hepatology 2004, 40(Suppl. 1), A1141.